Alector Stock Today
| ALEC Stock | USD 1.45 0.02 1.40% |
PerformanceVery Weak
| Odds Of DistressAbove Average
|
Alector is trading at 1.45 as of the 16th of March 2025, a 1.40 percent increase since the beginning of the trading day. The stock's open price was 1.43. Alector has over 57 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of February 2019 | Category Healthcare | Classification Health Care |
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. The company was founded in 2013 and is headquartered in South San Francisco, California. Alector operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 99.09 M outstanding shares of which 5.61 M shares are presently shorted by private and institutional investors with about 8.94 trading days to cover. More on Alector
Moving together with Alector Stock
Moving against Alector Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Alector Stock Highlights
| CEO | Arnon Rosenthal | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAlector can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alector's financial leverage. It provides some insight into what part of Alector's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alector (ALEC) is traded on NASDAQ Exchange in USA. It is located in 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 238 people. Alector is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 143.67 M. Alector conducts business under Biotechnology sector and is part of Health Care industry. The entity has 99.09 M outstanding shares of which 5.61 M shares are presently shorted by private and institutional investors with about 8.94 trading days to cover.
Alector currently holds about 808.85 M in cash with (229.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Alector Probability Of Bankruptcy
Ownership AllocationAlector holds a total of 99.09 Million outstanding shares. The majority of Alector outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alector to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alector. Please pay attention to any change in the institutional holdings of Alector as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Alector Ownership Details
Alector Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 1.1 M | |
| 5am Venture Management, Llc | 2024-12-31 | 995.8 K | |
| Ikarian Capital, Llc | 2024-12-31 | 950 K | |
| Franklin Resources Inc | 2024-12-31 | 930.5 K | |
| Renaissance Technologies Corp | 2024-12-31 | 915.7 K | |
| Dafna Capital Management Llc | 2024-12-31 | 912.9 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 882.1 K | |
| Northern Trust Corp | 2024-12-31 | 759.9 K | |
| T. Rowe Price Associates, Inc. | 2024-12-31 | 746.1 K | |
| Fmr Inc | 2024-12-31 | 14.7 M | |
| Ra Capital Management, Llc | 2024-12-31 | 9.7 M |
Alector Historical Income Statement
Alector Stock Against Markets
Alector Corporate Management
| Virginia MBA | Chief Strategy | Profile | |
| Norah Conway | Program Portfolio | Profile | |
| Gary MD | Chief Officer | Profile | |
| Katie Hogan | Senior Relations | Profile |
Already Invested in Alector?
The danger of trading Alector is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alector is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alector. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alector is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alector offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alector's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alector Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alector Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alector. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Alector Stock refer to our How to Trade Alector Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alector. If investors know Alector will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alector listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.86) | Earnings Share (1.23) | Revenue Per Share | Quarterly Revenue Growth 2.571 | Return On Assets |
The market value of Alector is measured differently than its book value, which is the value of Alector that is recorded on the company's balance sheet. Investors also form their own opinion of Alector's value that differs from its market value or its book value, called intrinsic value, which is Alector's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alector's market value can be influenced by many factors that don't directly affect Alector's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alector's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alector is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alector's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.